Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068432 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 11
- Study locations
NCT00068432: Completed Phase 2 study of Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00068432 is a Phase 2 study of Pancreatic Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068432, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 11
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with celecoxib works in treating patients with metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG Celecoxib
- DRUG Gemcitabine Hydrochloride
Study Locations (11)
Missouri
- CCOP - Kansas City - Kansas City
- CCOP - Cancer Research for the Ozarks - Springfield
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
Florida
- M.D. Anderson Cancer Center - Orlando - Orlando
Georgia
- CCOP - Atlanta Regional - Atlanta
Illinois
- CCOP - Carle Cancer Center - Urbana
Kansas
- CCOP - Wichita - Wichita
Ohio
- CCOP - Dayton - Dayton
Oregon
- CCOP - Columbia River Oncology Program - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00068432 record still lists
NCT00068432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Celecoxib is the first listed.
NCT00068432 lists 11 locations in 10 states (Missouri, Arkansas, Florida).
Frequently Asked Questions
What is clinical trial NCT00068432 about?
NCT00068432 is a clinical study titled "Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gem...
What is the current status of trial NCT00068432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2003-12. Estimated completion is 2005-07.
What conditions does trial NCT00068432 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00068432?
The interventions under investigation include: Celecoxib (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00068432?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00068432 being conducted?
This trial has 11 study locations across Arkansas, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00068432's enrollment target sits among peer trials
28 199th of 278 higher than 76 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia